, Volume 7, Issue 2, pp 83–87 | Cite as

Pituitary Apoplexy During Therapy with Cabergoline in an Adolescent Male with Prolactin-Secreting Macroadenoma

  • Mirta Knoepfelmacher
  • Miriam C. Gomes
  • Maria E. Melo
  • Berenice B. Mendonca


Pituitary adenomas are rare in young patients. Prolactinomas are the most common type of pituitary adenomas in children older than 12 years, occurring more often in girls, at a 4.5:1 female-to-male ratio. The clinical presentation may vary according to the age and sex of the patient. Pituitary apoplexy is a rare life-threatening condition caused by a sudden infarction or hemorrhagic necrosis of the pituitary containing an adenoma. A wide variety of conditions can trigger apoplexy such as pituitary irradiation, general anesthesia, traumatic head injury, pituitary stimulatory tests and a wide variety of medications including bromocriptine. We report a case of a 16-year-old male patient with puberty arrest harboring a macroprolactinoma, who developed a sudden clinical picture of pituitary apoplexy during the 12th month of treatment with cabergoline.

Key Words

pituitary apoplexy macroprolactinoma cabergoline puberty arrest 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Rolih CA, Ober KP. Pituitary apoplexy. Endocrinology and Metabolism Clin N Am 1993;22:291–302.Google Scholar
  2. 2.
    Randeva HS, Schoebel J, Byrne J, Esiri M, Adams CBT, Wass JAH. Classical pituitary apoplexy: Clinical features, management and outcome. Clin Endocrinol 1999;51:181–188.CrossRefGoogle Scholar
  3. 3.
    Biousse V, Newman NJ, Oyesiku NM. Precipitating factors in pituitary apoplexy. J Neurol Neuros and Psych 2001;71:542–545.Google Scholar
  4. 4.
    Yamajix J, Ishibashi M, Kosaka K, Hori T, Manaka S. Pituitary apoplexy in acromegaly during bromocriptine therapy. Acta Endocrinol(Copenh.) 1981;98(2):171–177.Google Scholar
  5. 5.
    Shirataki K, Chihara K, Shibata Y, Tamaki N, Matsumoto S, Fujita T. Pituitary apoplexy manifested during a bromocriptine test in a patient with growth hormone and prolactin producing pituitary adenoma. Neurosurgery 1988;23:395–398.PubMedGoogle Scholar
  6. 6.
    Pinto G, Zerah M, Trivin C, Brauner R. Pituitary apoplexy in an adolescent with prolactin-secreting adenoma. Hormone Research 1998;50:38–41.CrossRefPubMedGoogle Scholar
  7. 7.
    Vance ML, Evans W, Thorner M. Bromocriptine Ann Intern Med 1984;100:78–91.Google Scholar
  8. 8.
    Liuzzi A, Dallabonzana D, Oppizzi G, Verde GG, Cozzi R, Chiodini P, Luccarelli G. Low dose of dopamine agonists in the long-term treatment of macroprolactinomas. N Engl J Med 1985;313:656–659.PubMedGoogle Scholar
  9. 9.
    Molitch ME, Elton RL, Blackwell RE, Caldwell B, Chang RJ, Jaffe R, Joplin G, Robbins RJ, Tyson J, Thorner MO. Bromocriptine as primary therapy for prolactin-secreting macroprolactinomas: Result of a prospective multicenter study. J Clin Endocrinol Metab 1985;60:698–705.PubMedGoogle Scholar
  10. 10.
    Biller BMK, Molitch ME, Vance ML,Cannistraro KB, Davis KR, Simons JA, Schoenfelder JR, Kklibanski A. Treatment of prolactin-secreting macroadenomas with once-weekly dopamine agonist cabergoline. J Clin Endocrinol Metab 1996;81:2338–2343.CrossRefPubMedGoogle Scholar
  11. 11.
    Ferrari CI, Abs R, Bevan JS, Brabant G,Ciccarelli E, Motta T, Mucci M, Muratori M, Musatti L, Verbessem G, Scanlon MF. Treatment of macroprolactinomas with cabergoline: A study of 85 patients. Clin Endocrinol (Oxf.) 1997;46:409–415.Google Scholar
  12. 12.
    Colao A, Di Sarno A, Landi ML, Crillo S, Sarnacchiaro F, Facciolli G, Annunziato L, Lombardi G. Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage. J Clin Endocrinol Metab 1997;82:3574–3579.PubMedGoogle Scholar
  13. 13.
    Verhelst J, Abs R, Maiter D, Van Den Bruel A, Vandeweghe M, Velkeniers B, Mockel J, Lamberigts, Perossians P, Coremans P, Mahler C, Stevenaert A, Verlooy J, Raftopoulos C, Beckers A. Cabergoline in the tretment of hyperprolactinemia: A study in 455 patients. J Clin Endocrinol Metab 1999;84:2518–2522.PubMedGoogle Scholar
  14. 14.
    Colao A, Loche S, Cappa M, Di Sarno A, Landi ML, Sarnacchiao F, Faccioli G, Lombardi, G. Prolactinomas in children and adolescents. Clinical presentation and long-term follow-up. J Clin Endocrinol Metab 1998;83:2777–2780.PubMedGoogle Scholar
  15. 15.
    Partington MD, Davis DH, Laws ER Jr, Scheithauer BW. Pituitary adenomas in childhood and adolescence: Results of transsphenoidal surgery. J Neuros 1994;80:209–216.Google Scholar
  16. 16.
    Mindermann T, Wilson CB. Pituitary adenomas in childhood and adolescence. Journal of Pediatric Endocrinology and Metaboslism 1995;8:79–83.Google Scholar
  17. 17.
    Knwar S, Wilson CB. Pediatric pituitary adenomas. J Clin Endocrinol Metab 1999;84:4385–4389.Google Scholar
  18. 18.
    Calle-Rodrigue RD, Gianni C, Scherthauer BW, Lloyd RV, Wollan PC, Kovacs KT, Stefaneanu L, Ebright AB, Abboud CF, Davis DH. Prolactinomas in male and female patients: A comparative clinical pathologic study. Mayo Clinic Proc 1998;73:1046–1052.Google Scholar
  19. 19.
    Delgrange E, Maiter D, Donckier J, Tourniare J. Influence of age on the clinical presentations of prolactinomas in male. Min Endocrinol 1998;23(1):7–16.Google Scholar
  20. 20.
    Tyson D, Reggiardo D, David R. Prolactin-secreting macroadenomas in adolescents. Response to bromocriptine therapy. Am J Dis Child 1993;147:1057–1061.PubMedGoogle Scholar
  21. 21.
    Delgrange E, Trouillas J, Maiter D, Donckier J, Tourniaire J. Sex-related difference in the growth of prolactinomas: A clinical and proliferation marker study. J Clin Endocrinol Metab 1997;82:2102–2107.CrossRefPubMedGoogle Scholar
  22. 22.
    Albuquerque PC, Hinton DR, Weiss MH. Excessively high prolactin level in a patient with a nonprolactin-secreting adenoma: Case report. J Neuros 1998;89:1043–1046.Google Scholar
  23. 23.
    Wakai S, Fukushima T, Teramoto A, Sano K. Pituitary apoplexy: Its incidence and clinical significance. J Neuros 1981;55:187–193.Google Scholar
  24. 24.
    Mohr G, Hardy J. Haemorrhage, necrosis and apoplexy in pituitary adenomas. Surg Neurol 1982;18:181–189.PubMedGoogle Scholar
  25. 25.
    Miranda M, Barros L, Knoepfelmacher M, Augusto E, Jacomosi A, Cukiert A, Salgado LR, Goldman J, Liberman B. Pituitary apoplexy followed by endocrine remission. Report of two cases. Arqu Neuro-Psiq 1998;56(3):449–452.Google Scholar
  26. 26.
    Knoepfelmacher M, Ursich M, Barros LM, Duarte A, Salgado LR, Pimentel-Filho FB, Liberman B. Insulin resistance associated to high levels of TNF during pituitary apoplexy induced by a pituitary stimulating test in an acromegalic patient. The Endocrinologist 2001;11:425–428.Google Scholar
  27. 27.
    Cardoso ER, Peterson EW. Pituitary apoplexy: A review. Neurosurgery 1984;14:363–373.PubMedGoogle Scholar
  28. 28.
    Colao A, Di Sarno A, Landi ML, Scavuzzo F, Cappabianca P, Pivonello R, Volpe R, Di Salle F, Cirillo S, Annunziato L, Lombardi G. Macroprolactinoma Shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: A prospective study in 110 patients. J Clin Endocrinol Metab 2000;87:2247-2252.Google Scholar

Copyright information

© Springer Science + Business Media, Inc. 2004

Authors and Affiliations

  • Mirta Knoepfelmacher
    • 1
    • 2
  • Miriam C. Gomes
    • 1
  • Maria E. Melo
    • 1
  • Berenice B. Mendonca
    • 1
  1. 1.Department of EndocrinologyHospital das Clínicas, University of São Paulo Medical SchoolSão PauloBrasil
  2. 2.São PauloBrasil

Personalised recommendations